NANBH
MCID: HPT001
MIFTS: 70

Hepatitis C (NANBH)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 12 76 55 43 44 15 73
Hepatitis C Infection 12 15
Hepatitis C, Chronic 73
Chronic Hepatitis C 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 55
Viral Hepatitis C 12
Nanbh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1883
ICD10 33 B19.2 B19.20
ICD9CM 35 070.7
MeSH 44 D006526
NCIt 50 C3098
SNOMED-CT 68 50711007

Summaries for Hepatitis C

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis C, is caused by the hepatitis C virus (HCV). It usually spreads through contact with infected blood. It can also spread through sex with an infected person and from mother to baby during childbirth. Most people who are infected with hepatitis C don't have any symptoms for years. If you do get symptoms, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. A blood test can tell if you have it. Usually, hepatitis C does not get better by itself. The infection can last a lifetime and may lead to cirrhosis (scarring of the liver) or liver cancer. Medicines sometimes help, but side effects can be a problem. Serious cases may need a liver transplant. There is no vaccine for HCV. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c infection, is related to hepatitis c virus and hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Intron A and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotype is immune system.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 696)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 33.9 CD81 CLDN1 CLDN6 DDX58 GPT IFNG
2 hepatitis 32.5 CD81 CLDN1 CLDN6 DDX58 GPT IFNA1
3 hepatitis b 31.4 GPT IFNA1 IFNA2 IFNG
4 cryoglobulinemia, familial mixed 31.4 IFNA1 IFNA2
5 viral infectious disease 31.3 CD81 DDX58 GPT IFNA1 IFNA2 IFNAR1
6 noonan syndrome 3 31.2 CD81 DDX58 IFNA1 IFNB1 IRF3 MAVS
7 viral hepatitis 31.2 GPT IFNA1 IFNA2 KRT18
8 liver cirrhosis 31.0 GPT HOTAIR IFNA1 KRT18
9 noonan syndrome 2 30.9 CD81 DDX58 IRF3 MAVS
10 hepatitis a 30.6 GPT IFNG MAVS
11 acquired immunodeficiency syndrome 30.3 IFNA1 IFNA2 IFNG
12 hepatitis e 30.2 GPT IFNG TLR3
13 oral erosive lichen 30.2 IFNA1 IFNB1
14 stomatitis 30.1 DDX58 IFNA2 LDLR
15 severe acute respiratory syndrome 30.0 IFNA1 IFNB1 IFNG IRF3
16 west nile virus 29.9 DDX58 IFNA1 IRF3 TLR3
17 kaposi sarcoma 29.9 IFNA1 IFNA2 IFNB1 IRF3
18 encephalitis 29.8 DDX58 IRF3 TLR3
19 influenza 29.8 DDX58 IFNA1 IFNB1 IFNG IRF3 TLR3
20 japanese encephalitis 29.8 DDX58 IFNB1 TLR3
21 renal cell carcinoma, nonpapillary 29.7 HOTAIR IFNA1 IFNA2 IFNG
22 herpes simplex 29.7 DDX58 IFNA1 IFNB1 IRF3 TLR3
23 variola major 29.6 IFNG TLR3
24 measles 29.4 DDX58 IFNA1 IFNB1 IFNG TLR3
25 chronic end-stage hepatitis c 12.2
26 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.1
27 hepatocellular carcinoma 11.6
28 liver disease 11.5
29 porphyria cutanea tarda 11.4
30 fatty liver disease 11.4
31 polyarteritis nodosa 11.4
32 fibrillary glomerulonephritis 11.4
33 opiate dependence 11.4
34 linear lichen planus 11.3
35 immunotactoid glomerulopathy 11.3
36 heroin dependence 11.3
37 immunotactoid or fibrillary glomerulopathy 11.3
38 pars planitis 11.0
39 intermediate uveitis 11.0
40 papular mucinosis 11.0
41 cryoglobulinemia 10.8
42 glomerulonephritis 10.6
43 lymphoma 10.6
44 porphyria 10.5
45 vasculitis 10.5
46 membranoproliferative glomerulonephritis 10.4
47 lichen planus 10.4
48 fatty liver disease, nonalcoholic 1 10.3
49 thalassemia 10.3
50 oral lichen planus 10.3

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • joint pain
  • loss of appetite
  • clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis C:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.32 CD81 DDX58 IFNAR1 IFNB1 IFNG IRF3

Drugs & Therapeutics for Hepatitis C

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 606)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
3
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
5
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99210-65-8, 215647-85-1
8
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
10
leucovorin Approved Phase 4,Phase 2,Phase 1 58-05-9 6006 143
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
12
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
13
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
15
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
16
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
17
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
18
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
19
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
20
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
21
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
22
Insulin Glargine Approved Phase 4 160337-95-1
23
Insulin glulisine Approved Phase 4 207748-29-6
24
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
25
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 923604-59-5 66576988
26
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
27 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
29
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
30
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
31
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
32
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139
33
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
34
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 134678-17-4 60825
35
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
36
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
37
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
38
Nevirapine Approved Phase 4 129618-40-2 4463
39
Rifaximin Approved, Investigational Phase 4,Phase 2,Not Applicable 80621-81-4 6436173
40
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
41
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
42
Losartan Approved Phase 4 114798-26-4 3961
43
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
44
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
45
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
46
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
47
Nelfinavir Approved Phase 4 159989-64-7 64143
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
50
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 1 376348-65-1 3002977

Interventional clinical trials:

(show top 50) (show all 2345)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
3 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
4 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
5 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
6 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
7 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
8 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
9 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
10 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
11 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
12 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
13 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
14 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
15 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
16 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
17 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
18 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
19 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
20 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
21 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
22 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. Unknown status NCT02802280 Phase 4
23 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
24 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
25 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
26 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
27 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
28 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
29 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
30 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
31 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
32 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
33 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
34 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
35 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
36 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
37 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
38 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
39 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
40 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
41 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
42 A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 Completed NCT01258101 Phase 4 peginterferon alfa-2a [Pegasys];peginterferon alfa-2a [Pegasys];ribavirin;ribavirin
43 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
44 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
45 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
46 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
47 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
48 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
49 A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment Completed NCT03212521 Phase 4 glecaprevir/pibrentasvir
50 Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection Completed NCT02377856 Phase 4 pegylated interferon alpha 2a, ribavirin

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

MalaCards organs/tissues related to Hepatitis C:

41
Liver, Testes, Kidney, T Cells, B Cells, Thyroid, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

19
Liver

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 10660)
# Title Authors Year
1
Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. ( 30548317 )
2019
2
Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C - authors' reply. ( 30548320 )
2019
3
Pharmacy-led hepatitis C treatment pathways to help ensure elimination. ( 30527577 )
2019
4
Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village. ( 30527578 )
2019
5
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. ( 30527582 )
2019
6
Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. ( 30467877 )
2019
7
Strategies for access to affordable hepatitis C testing and treatment in Asia. ( 30480583 )
2019
8
HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region. ( 30489347 )
2019
9
The Revolution in Treatment of Hepatitis C. ( 30466675 )
2019
10
TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )
2019
11
Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. ( 30401643 )
2019
12
Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. ( 30239347 )
2019
13
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. ( 30247174 )
2019
14
Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. ( 30133717 )
2019
15
Human pegivirus isolates characterized by deep sequencing from hepatitis C virus-RNA and human immunodeficiency virus-RNA-positive blood donations, France. ( 30133782 )
2019
16
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. ( 30142097 )
2019
17
Skeletal muscle mass depletion in patients with hepatitis C virus infection. ( 30179904 )
2019
18
Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. ( 30199473 )
2019
19
Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay. ( 30091789 )
2019
20
Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. ( 30024489 )
2019
21
Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production ( 30056690 )
2019
22
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
23
Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )
2018
24
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
25
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
26
Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )
2018
27
Hepatitis C screening in patients with oral lichen planus. ( 29971956 )
2018
28
Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. ( 29248968 )
2018
29
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
30
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
31
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
32
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )
2018
33
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
34
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with I^-Thalassemia Major. ( 29743790 )
2018
35
HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. ( 29981093 )
2018
36
Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. ( 29962673 )
2018
37
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
38
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
39
Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. ( 29974665 )
2018
40
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. ( 29399747 )
2018
41
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients. ( 29290175 )
2018
42
Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor? ( 29935864 )
2018
43
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
44
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
45
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
46
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. ( 29271782 )
2018
47
Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. ( 29975243 )
2018
48
microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. ( 29973597 )
2018
49
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. ( 29022122 )
2018
50
Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )
2018

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
2
Show member pathways
12.96 DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
3
Show member pathways
12.91 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3 TLR3
4
Show member pathways
12.89 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG IRF3
5
Show member pathways
12.59 DDX58 IFNA1 IFNA2 IFNB1 IFNG IRF3
6
Show member pathways
12.5 DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
7 12.49 DDX58 IFNA1 IFNG IRF3 MAVS TLR3
8
Show member pathways
12.42 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
9
Show member pathways
12.4 DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
10
Show member pathways
12.32 DDX58 IRF3 MAVS TLR3
11
Show member pathways
12.3 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
12
Show member pathways
12.23 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
13
Show member pathways
12.2 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG IRF3
14 12.14 IFNA1 IFNA2 IFNB1 IFNG
15
Show member pathways
12.12 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG TLR3
16 12.1 DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
17 12.07 IFNA1 IFNA2 IFNB1 IRF3
18 11.91 IFNAR1 IFNB1 IFNG
19 11.8 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
20 11.64 IFNA2 IFNB1 IFNG
21 11.55 CD81 CLDN1 CLDN6 DDX58 IFNA1 IFNA2
22 11.38 IFNA1 IFNA2 IFNB1
23 11.3 IFNA2 IFNB1 IFNG
24 10.82 IFNAR1 IFNB1
25
Show member pathways
10.72 DDX58 IFNA2 IFNAR1 IRF3 MAVS

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bicellular tight junction GO:0005923 9.33 CLDN1 CLDN6 DDX58
2 extracellular space GO:0005615 9.23 GPT IFNA1 IFNA2 IFNB1 IFNG IFNL4
3 endolysosome membrane GO:0036020 8.96 LDLR TLR3

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.98 IFNA1 IFNA2 IFNB1 IFNG
2 cytokine-mediated signaling pathway GO:0019221 9.98 IFNA1 IFNA2 IFNAR1 IFNB1
3 cell surface receptor signaling pathway GO:0007166 9.97 CD81 IFNA2 IFNB1 IFNG
4 defense response GO:0006952 9.88 IFNA1 IFNA2 IFNB1 TLR3
5 response to virus GO:0009615 9.85 DDX58 IFNAR1 IFNB1 IFNG TLR3
6 viral entry into host cell GO:0046718 9.83 CD81 CLDN1 CLDN6 LDLR SCARB1
7 B cell differentiation GO:0030183 9.82 IFNA1 IFNA2 IFNB1
8 viral process GO:0016032 9.81 CD81 CLDN1 CLDN6 DDX58 IRF3 KRT18
9 humoral immune response GO:0006959 9.78 IFNA1 IFNA2 IFNB1 IFNG
10 extrinsic apoptotic signaling pathway GO:0097191 9.77 IFNG KRT18 TLR3
11 B cell proliferation GO:0042100 9.74 IFNA1 IFNA2 IFNB1
12 negative regulation of type I interferon production GO:0032480 9.73 DDX58 IRF3 MAVS
13 positive regulation of interleukin-8 production GO:0032757 9.72 DDX58 MAVS TLR3
14 type I interferon signaling pathway GO:0060337 9.72 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
15 positive regulation of interferon-beta production GO:0032728 9.71 DDX58 IRF3 MAVS TLR3
16 T cell activation involved in immune response GO:0002286 9.7 IFNA1 IFNA2 IFNB1
17 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.69 CLDN1 CLDN6
18 natural killer cell activation involved in immune response GO:0002323 9.69 IFNA1 IFNA2 IFNB1
19 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.68 CD81 LDLR
20 cellular response to interferon-beta GO:0035458 9.68 IFNB1 TLR3
21 positive regulation of tumor necrosis factor secretion GO:1904469 9.67 DDX58 MAVS
22 positive regulation of interferon-alpha production GO:0032727 9.67 DDX58 IRF3 MAVS
23 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.67 IFNA1 IFNA2 IFNB1 IFNG
24 positive regulation of protein import into nucleus, translocation GO:0033160 9.66 IFNG MAVS
25 positive regulation of triglyceride biosynthetic process GO:0010867 9.66 LDLR SCARB1
26 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.65 IRF3 MAVS
27 high-density lipoprotein particle clearance GO:0034384 9.65 LDLR SCARB1
28 positive regulation of interferon-alpha secretion GO:1902741 9.65 DDX58 MAVS
29 cellular response to dsRNA GO:0071359 9.63 IRF3 TLR3
30 cholesterol import GO:0070508 9.63 LDLR SCARB1
31 negative regulation of T cell differentiation GO:0045581 9.62 IFNA2 IFNB1
32 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.62 DDX58 MAVS
33 positive regulation of response to cytokine stimulus GO:0060760 9.61 DDX58 MAVS
34 detection of virus GO:0009597 9.61 DDX58 TLR3
35 positive regulation of interferon-beta secretion GO:0035549 9.6 DDX58 MAVS
36 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.58 IFNA2 IFNB1
37 cellular response to exogenous dsRNA GO:0071360 9.56 DDX58 IFNB1 MAVS TLR3
38 regulation of phosphatidylcholine catabolic process GO:0010899 9.54 LDLR SCARB1
39 response to exogenous dsRNA GO:0043330 9.43 DDX58 IFNA1 IFNA2 IFNB1 IRF3 TLR3
40 defense response to virus GO:0051607 9.28 DDX58 IFNA1 IFNA2 IFNB1 IFNG IFNL4
41 innate immune response GO:0045087 10.06 DDX58 IFNL4 IRF3 MAVS TLR3
42 regulation of signaling receptor activity GO:0010469 10.04 IFNA1 IFNA2 IFNB1 IFNG IFNL4

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 CLDN1 CLDN6 DDX58 IRF3 LDLR TLR3
2 cytokine activity GO:0005125 9.55 IFNA1 IFNA2 IFNB1 IFNG IFNL4
3 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
4 low-density lipoprotein particle binding GO:0030169 9.32 LDLR SCARB1
5 type I interferon receptor binding GO:0005132 9.13 IFNA1 IFNA2 IFNB1
6 virus receptor activity GO:0001618 9.02 CD81 CLDN1 CLDN6 LDLR SCARB1

Sources for Hepatitis C

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris </